Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021923 | 0.76 | SLC6A4 (0.36) | SLC6A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6781560 | 0.69 | SLC6A4 (0.32) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL15850531 | 0.65 | SLC6A3 (0.46) | SLC6A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5507381 | 0.65 | SLC6A2 (0.38) | SLC6A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4025455 | 0.63 | HSD11B1 (0.38) | KMT2A | |
| SCHEMBL6916553 | 0.62 | CHRM3 (0.48) | SLC6A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4021039 | 0.62 | SLC6A3 (0.36) | SLC6A3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4021580 | 0.61 | SLC6A2 (0.43) | CHRM2CHRM5CHRM3SLC6A4OPRM1 | |
| SCHEMBL27715365 | 0.60 | NPC1 (0.38) | SLC6A3KMT2AMEN1 | |
| SCHEMBL6595795 | 0.59 | SLC6A3 (0.40) | SLC6A3CHRM3SLC6A4OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070219262-A1 | omega-Cycloalkyl 17-Heteroaryl Prostaglandin E2 Analogs as EP2-Receptor Agonists | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
| US-7223746-B2 | Omega cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1438104-B1 | CO-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-7022726-B2 | ω-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1442033-B1 | OMEGA-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050113338-A1 | Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2005-05-26 | — | — | US | disclosed |
| US-20040106580-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN INC. | 2004-06-03 | — | — | US | disclosed |
| US-6710072-B2 | VISION DEFECTS | ALLERGAN, INC. | 2004-03-23 | — | — | US | disclosed |
| US-20030130239-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6586462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-01 | — | — | US | disclosed |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2002-12-12 | — | — | US | disclosed |
| US-6376533-B1 | VISION DEFECTS | ALLERGAN SALES, INC. | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130239-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER4, PTGER1 | SLC6A3 4009/4885CHRM2 425/4885CHRM4 364/4885 |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER1, PTGER3 | SLC6A3 4129/4885CHRM2 451/4885CHRM4 1095/4885 |
| US-20070219262-A1 | omega-Cycloalkyl 17-Heteroaryl Prostaglandin E2 Analogs as EP2-Receptor Agonists | PTGER4, PTGER2, LTB4R2 | SLC6A3 3881/4885CHRM2 332/4885CHRM4 132/4885 |
| US-20050113338-A1 | Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER4, PTGER2, LTB4R2 | SLC6A3 3943/4885CHRM2 348/4885CHRM4 168/4885 |
| US-20040106580-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER4, PTGER1 | SLC6A3 4076/4885CHRM2 419/4885CHRM4 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.